Avid expands Californian PD and lab capabilities

PD is a vital CDMO function and one that Avid will continue to invest in, the firm says as it opens a multi-million-dollar expansion in Orange County.

Dan Stanton, Managing editor

October 17, 2019

2 Min Read
Avid expands Californian PD and lab capabilities
Image: iStock/Christopher-Oliver

Process development (PD) is a vital CDMO function and one that Avid will continue to invest in, the firm says as it opens a multi-million-dollar expansion in Orange County.

Avid Bioservices opened the doors on an expansion at its site in Orange County, California last week. The multi-million-dollar investment increases the contract development and manufacturing organization (CDMO) process development (PD) laboratory footprint four-fold, adding 24 benchtop process development bioreactors, ranging from 3 liter to 15-liter capacity in single-use and glass.


Image: iStock/Christopher-Oliver

The “strategic expansion and enhancement of its process development capabilities and laboratories involved a multi-million-dollar investment from the company,” an Avid spokesperson told this publication.

Process development represents a “vital CDMO function” and one that “provides a critical advantage to customers in both early and late stages,” the spokesperson said.

“As such, it is an area within which the company will continue to work to strengthen its position as a leader in the CDMO space. Importantly, the completed expansion project further enhances the company’s capabilities in not only process development, but also in the areas of R&D support, process characterization and validation, and pilot scale production for a broad range of biotechnology products.”

The additional 6,000 square feet of dedicated process development lab space at the Franklin, California facility, was first announced in October 2018. At the time, the CDMO said the expansion would triple the company’s process development capacity and will feed demand from global clients seeking to transition their products into early stage clinical manufacturing.

“Avid’s laboratory expansion provides the company with added capabilities, allowing Avid to perform stand-alone process development and accelerate the onboarding of clients,” the spokesperson told us.

“The company now has 30 state-of-the-art scaled down bioreactors, which allows Avid to undertake sophisticated designs of experiments for our clients to support their process validation.”

Related news: Avid contemplates pulling the trigger on capacity expansion

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like